|
Conjugated Estrogens
|
Conjugated estrogens, a mixture of the water-soluble salts of sulfate esters from estrone, equilin, 17 -dihydroequilin, and other related steroids, may be derived from pregnant equine urine or yam and soy plants. Estrogens are important in the development and maintenance of the female reproductive system and secondary sex characteristics. Pharmacology: Conjugated estrogens, a mixture of the water soluble salts of sulfate esters from estrone, equilin, 17 -dihydroequilin, and other related steroids, may be derived from pregnant equine urine or yam and soy plants. Estrogens are important in the development and maintenance of the female reproductive system and secondary sex characteristics. They promote growth and development of the vagina, uterus, and fallopian tubes, and enlargement of the breasts. Indirectly, they contribute to the shaping of the skeleton, maintenance of tone and elasticity of urogenital structures, changes in the epiphyses of the long bones that allow for the pubertal growth spurt and its termination, growth of axillary and pubic hair, and pigmentation of the nipples and genitals. Decline of estrogenic activity at the end of the menstrual cycle can bring on menstruation, although the cessation of progesterone secretion is the most important factor in the mature ovulatory cycle. However, in the preovulatory or nonovulatory cycle, estrogen is the primary determinant in the onset of menstruation. Estrogens also affect the release of pituitary gonadotropins. The pharmacologic effects of conjugated estrogens are similar to those of endogenous estrogens. Mechanism of action: Estrogens enter the cells of responsive tissues (e.g., female organs, breasts, hypothalamus, pituitary) where they interact with a protein receptor, subsequently increasing the rate of synthesis of DNA, RNA, and some proteins. Estrogens decrease the secretion of gonadotropin-releasing hormone by the hypothalamus, reducing the secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary. Drug type: Approved. Small Molecule. Drug category: Estrogens
|
ILX:0102481
|
3
|
scicrunch
|
06/18/2018
|
scicrunch |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Connected spatiotemporal region
|
|
ILX:0102482
|
2
|
scicrunch
|
01/17/2018
|
scicrunch |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Connected temporal region
|
|
ILX:0102483
|
2
|
scicrunch
|
01/17/2018
|
scicrunch |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Connectional specificity
|
The principle that neurons form specific functional interconnections, based on three anatomical observations: 1. there is no cytoplasmic continuity between nerve cells; 2. neurons do not connect indiscriminately to one another or form random networks; 3. each cell communicates with specific postsynaptic cells but not with others, and always at specialized sites (synapses).
|
ILX:0102484
|
5
|
scicrunch
|
06/18/2018
|
scicrunch |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Connectionist model
|
A model of neural function with parallel and distributed processing components. Also neural net model.
|
ILX:0102485
|
5
|
scicrunch
|
06/18/2018
|
scicrunch |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Connectivity matrix
|
|
ILX:0102486
|
5
|
scicrunch
|
06/18/2018
|
scicrunch |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Connexin
|
A group of homologous proteins which form the intermembrane channels of gap junctions. The connexins are the products of an identified gene family which has both highly conserved and highly divergent regions. The variety contributes to the wide range of functional properties of gap junctions (MSH).
|
ILX:0102487
|
4
|
scicrunch
|
06/18/2018
|
scicrunch |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Connexin 32
|
|
ILX:0102488
|
4
|
scicrunch
|
06/18/2018
|
scicrunch |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Connexin 43
|
A 43 kD peptide which is a member of the connexin family of gap junction proteins. Connexin 43 is a product of a gene in the alpha class of connexin genes (the alpha-1 gene). It was first isolated from mammalian heart, but is widespread in the body including the brain (MSH).
|
ILX:0102489
|
4
|
scicrunch
|
06/18/2018
|
scicrunch |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Connexon
|
Assembly of 6 connexins into a hemichannel that forms one half of an intercellular channel. The intercellular channel is formed by the dimerization of the two connexons. In some cells, the hemichannel is active as a conduit between the cytoplasm and the extracellular space.
|
ILX:0102490
|
9
|
scicrunch
|
06/18/2018
|
scicrunch |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Consciousness
|
the quality or state of being aware especially of something within oneself; the state or fact of being conscious of an external object, state, or fact; the state of being characterized by sensation, emotion, volition, and thought; the totality of conscious states of an individual; the normal state of conscious life,(regained consciousness); the upper level of mental life of which the person is aware as contrasted with unconscious processes.
|
ILX:0102491
|
4
|
scicrunch
|
06/18/2018
|
scicrunch |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Consciousness Disorder
|
Organic mental disorders in which there is impairment of the ability to maintain awareness of self and environment and to respond to environmental stimuli. Dysfunction of the cerebral hemispheres or brain stem RETICULAR FORMATION may result in this condition (MeSH
|
ILX:0102492
|
3
|
scicrunch
|
06/18/2018
|
scicrunch |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Consistency
|
A physical quality that inheres in a continuant by virtue of density, firmness, or viscosity.
|
ILX:0102493
|
3
|
scicrunch
|
06/18/2018
|
scicrunch |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Consortium
|
Independent organizations formally working together toward a common goal, under an expressed agreement. (VIVO)
|
ILX:0102494
|
3
|
scicrunch
|
06/18/2018
|
scicrunch |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Conspicuous
|
A quality inhering in a bearer by virtue of its being clearly visibile.
|
ILX:0102495
|
3
|
scicrunch
|
06/18/2018
|
scicrunch |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Conspicuousness
|
A quality inhering in a bearer by virtue of its visibility.
|
ILX:0102496
|
3
|
scicrunch
|
06/18/2018
|
scicrunch |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Constant-pressure calorimetry instrument
|
|
ILX:0102497
|
3
|
scicrunch
|
06/18/2018
|
scicrunch |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Constant-volume calorimetry instrument
|
|
ILX:0102498
|
3
|
scicrunch
|
06/18/2018
|
scicrunch |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Constitutional part of cell
|
|
ILX:0102499
|
3
|
scicrunch
|
06/18/2018
|
scicrunch |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Constraint Weight
|
Relative importance of satisfying constraint, where high values represent more important constraints.
|
ILX:0102500
|
4
|
scicrunch
|
06/18/2018
|
scicrunch |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |